Glucocorticoids - New Recognition of Our Familiar Friend 2012
DOI: 10.5772/53909
|View full text |Cite
|
Sign up to set email alerts
|

Corticosteroids for Skin Delivery: Challenges and New Formulation Opportunities

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
15
0
1

Year Published

2014
2014
2023
2023

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(16 citation statements)
references
References 79 publications
0
15
0
1
Order By: Relevance
“…In the next step, the glucocorticoid DXM was selected as a therapeutically relevant drug from daily practice, and loaded onto CMS nanocarriers. Topical corticosteroid administration is a benchmark therapy for inflammatory skin diseases such as atopic dermatitis [65]. Well in line with the NR penetration studies, the CMS nanocarriers delivered DXM significantly more efficient (~ 3-fold) into the viable epidermis of excised human skin compared to the commercially available DXM cream (Fig.…”
Section: Dermal Drug Delivery Efficiencymentioning
confidence: 91%
See 1 more Smart Citation
“…In the next step, the glucocorticoid DXM was selected as a therapeutically relevant drug from daily practice, and loaded onto CMS nanocarriers. Topical corticosteroid administration is a benchmark therapy for inflammatory skin diseases such as atopic dermatitis [65]. Well in line with the NR penetration studies, the CMS nanocarriers delivered DXM significantly more efficient (~ 3-fold) into the viable epidermis of excised human skin compared to the commercially available DXM cream (Fig.…”
Section: Dermal Drug Delivery Efficiencymentioning
confidence: 91%
“…6). Furthermore, the effectiveness of corticosteroids is directly related to the composition of its formulation, and incorporation in cream is known to reduce their efficacy [65]. …”
Section: Anti-inflammatory Efficiency Of Dxm Loaded Ester-based Cms Nmentioning
confidence: 99%
“…However, the use of topical glucocorticoids can result in several local and adverse systemic effects, such as epidermis, dermis, or even subcutaneous tissue atrophy, resulting in irreversible stretch marks and in disorder of the wound-healing processes. Adverse systemic effects include body weight increase, Cushing's syndrome, hypertension, diabetes mellitus, growth retardation, osteoporosis, peptic ulcer, and gastritis (Schacke, Docke, Asadullah, 2002;Senyigit, Ozer, 2012).…”
Section: Introductionmentioning
confidence: 99%
“…However, due to its high potency, it displays dose-dependent toxicity and local and systemic adverse effects. In order to reduce the drug toxicity and to improve its action, halcinonide can be encapsulated into nanostructured systems, such as nanoparticles, which promote a controlled release of the drug in specific sites (Schaffazick, Guterres, 2003;Senyigit, Ozer, 2012). Nanostructured systems, such as nanoparticles, are submicron size ranged-usually spherical-drug carriers.…”
Section: Introductionmentioning
confidence: 99%
“…to increase their topical bioavailability, to deliver them to the skin as target siteepidermis and/or dermis -and to reduce the dose and frequency of administration for better safety [6,7]. Apart from the development of new molecules, one of the main strategies currently studied to overcome these challenges is the use of drug delivery systems.…”
mentioning
confidence: 99%